MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma

The purpose of this study is to find out if the study drug, [177Lu]Lu-DOTATATE, is better or worse than the usual drug therapy in treating meningioma that has come back after treatment with surgery, radiation, and/or drug therapy. [177Lu]Lu-DOTATATE is a radioactive drug, called a radiopharmaceutical, that works by targeting only the tumor and then delivering radiation into the tumor. [177Lu]Lu-DOTATATE has already been approved by the Food and Drug Administration (FDA) to treat other types of tumors, but it has not been approved to treat meningiomas.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years or older - Must have a confirmed diagnosis of grade 1-3 meningioma - Must must be willing and able to undergo regular magnetic resonance imaging (MRI) scans of the brain